Why hasn't eliminating acute rejection improved graft survival?
about
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsSubgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantationFlt3L combined with rapamycin promotes cardiac allograft tolerance by inducing regulatory dendritic cells and allograft autophagy in mice.Fibrosis with inflammation at one year predicts transplant functional decline.Th17 cells and transplant acceptancePolyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology.Calcineurin inhibitor-free immunosuppression in kidney transplantation.Nonhuman primate infections after organ transplantation.Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.Antibody responses to recombinant polyomavirus BK large T and VP1 proteins in young kidney transplant patients.High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients.Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation.Effects of Neutralization by Soluble ABH Antigens Produced by Transplanted Kidneys From ABO-Incompatible Secretor Donors.Noninvasive methods to assess the risk of kidney transplant rejection.DNA vaccines for transplantation.Profile of belatacept and its potential role in prevention of graft rejection following renal transplantationImmune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.The role of complement in antibody-mediated rejection in kidney transplantation.The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation.Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.Through a glass darkly: seeking clarity in preventing late kidney transplant failureDeveloping renal allograft surveillance strategies - urinary biomarkers of cellular rejection.Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.HHEX: A Crosstalker between HCMV Infection and Proliferation of VSMCs.Endothelial Cell Apoptosis Induces TGF-β Signaling-Dependent Host Endothelial-Mesenchymal Transition to Promote Transplant Arteriosclerosis.Delivery of rapamycin to dendritic cells using degradable microparticles.Targets of new immunosuppressants in renal transplantation.Reduction of chronic allograft nephropathy by inhibition of extracellular signal-regulated kinase 1 and 2 signaling.Vascular smooth muscle cell apoptosis promotes transplant arteriosclerosis through inducing the production of SDF-1α.Improving long-term renal allograft survival via a road less traveled by.Reduction of chronic rejection of renal allografts by anti-transforming growth factor-β antibody therapy in a rat model
P2860
Q24187213-04722128-6A10-43C3-A61E-068C6196AD20Q34382549-0E792742-9B5B-470C-A201-1EFEA968EAC7Q34441235-4002FE23-CEF4-4B48-9811-76F9D65EE493Q34457101-FBA8556A-41BF-4710-B336-1014C79A10ABQ35327827-4E4F8579-AF97-4CFA-AA06-3928941A86FBQ36537931-C16ECB2F-6FF2-48C9-B09F-DDBC71018B10Q36889001-6DEEE3A2-E255-45B2-A414-40BB8FBF7F5DQ36925928-D01719FD-7B9B-4A58-9259-53A96B121CA9Q37097694-8E28B716-3C2D-4138-B608-DCAEB13F4E35Q37302119-3C35E37D-7660-4457-9855-6992FE736DBAQ37349333-6D0CA165-5352-4E8C-8923-3277CF8156A5Q37438354-E4CE677E-4182-40CE-B66E-63BA9EC4120AQ37682997-5AF13380-CC0F-4D9A-BE52-F81BE5C05709Q37693693-9DA9ECA7-8835-4700-9671-C1482EE259A6Q37725897-8B703F57-F678-4B91-9548-2493AAE5818DQ37820147-27422DEA-8E51-4954-BDA3-5A8A170C237AQ37993738-425EF49E-D2F1-47E3-8D8B-0DEF04DA355EQ38048605-CCB3F420-EC32-41EC-836E-CD96E08FB503Q38228330-8607DB8A-2D2D-43B9-A2DA-DFEDE4A62EF4Q38230449-00108853-A742-4AB4-B52A-7310A38D695AQ38237365-0E3F7A22-74A8-4B05-817F-F678AF7DCD18Q38569092-3530E86B-2D35-408E-9F83-2CD74E0F62D5Q39801574-4B076113-61D8-4838-B815-14259DA8C7D8Q40410947-073378B8-0F54-43A0-B218-3AC1A68C6B6FQ40537003-5CB386F0-DF87-4D54-B418-A1CFF2367CBAQ41842968-6501A6DC-1981-4FCD-ACA4-878B33BC2ABCQ42727530-9B23F15F-2019-4DC3-8225-431DF3B560F1Q46492805-83A4F48C-254E-4560-A8D1-23C33BC9E3D2Q53154105-58C2B550-DAE1-49D5-9682-BC5F3BDA52A3Q53425445-0E24E1F2-CA48-4C29-B85D-610A5D7D42CEQ56704568-82FA6F37-B22F-42A2-8291-8FF6CE191D16
P2860
Why hasn't eliminating acute rejection improved graft survival?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Why hasn't eliminating acute rejection improved graft survival?
@ast
Why hasn't eliminating acute rejection improved graft survival?
@en
type
label
Why hasn't eliminating acute rejection improved graft survival?
@ast
Why hasn't eliminating acute rejection improved graft survival?
@en
prefLabel
Why hasn't eliminating acute rejection improved graft survival?
@ast
Why hasn't eliminating acute rejection improved graft survival?
@en
P2093
P1476
Why hasn't eliminating acute rejection improved graft survival?
@en
P2093
Bruce Kaplan
JogiRaju Tantravahi
Karl L Womer
P304
P356
10.1146/ANNUREV.MED.58.061705.145143
P577
2007-01-01T00:00:00Z